Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Erelzi

Canada Approves Erelzi for PsA; Plus FDA Moves to Increase Access to Naloxone

Michele B. Kaufman, PharmD, BCGP  |  February 4, 2019

Health Canada has approved Erelzi, which is biosimilar to Enbrel (etanercept), for treating psoriatic arthritis in adults…

Filed under:AnalgesicsDrug Updates Tagged with:Biologics & BiosimilarsBiosimilarsCanadaetanerceptFDAgeneric drug marketnaloxoneopioidOpioid abusePsoriatic ArthritisU.S. Food and Drug Administration (FDA)

Psoriatic Arthritis Drugs at a Glance, 2023

Mary Choy, PharmD, BCGP, FASHP  |  April 21, 2023

Biosimilars have become a therapeutic turning point for many patients who are living with rheumatic illnesses. Psoriatic arthritis (PsA) is a complex, multi-faceted chronic inflammatory musculoskeletal and skin disease where the treatment has changed considerably over the past few years. Psoriatic arthritis has an impact on about 30% of people with psoriasis.1 In 2019, the…

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:PsA Resource CenterPsoriatic Arthritis

Andrew Brookes / Image Source on Offset

Clinical Insights into Axial Spondyloarthritis: Rheumatology Drugs at a Glance, Part 5

Mary Choy, PharmD, BCGP, FASHP  |  February 10, 2022

Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options; others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…

Filed under:Axial SpondyloarthritisBiologics/DMARDsConditionsDrug Updates Tagged with:Ankylosing SpondylitisAS Resource Center

Psoriatic Arthritis Treatment Update

Mary Choy, PharmD, BCGP, FASHP  |  October 13, 2021

About 30% of patients with psoriasis have psoriatic arthritis (PsA), a complex, multi-faceted, chronic, inflammatory musculoskeletal and skin disease for which the treatment has changed considerably over the past few years.1 Biosimilars and other new drugs have become a therapeutic turning point for many patients suffering from rheumatic illnesses, including PsA. The treatment of PsA…

Filed under:Clinical Criteria/GuidelinesConditionsDrug UpdatesPsoriatic Arthritis Tagged with:PsA Resource CenterPsoriatic Arthritis

Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

Mary Choy, PharmD, BCGP, FASHP  |  August 16, 2019

Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:abataceptadalimumabanakinrabaricitinibCertolizumab PegoletanerceptGolimumabinfliximabrituximabsarilumabtocilizumabTofacitinib

Amgen Wins U.S. Patent Battle on Arthritis Drug Enbrel

Deena Beasley  |  August 12, 2019

(Reuters)—A U.S. judge on Friday upheld two patents relating to Amgen Inc,’s blockbuster rheumatoid arthritis drug Enbrel (etanercept), denying a challenge by Novartis AG, which is seeking to launch a biosimilar version. The decision was a relief to investors concerned about a competitive threat to Enbrel, which had U.S. sales of $4.8 billion last year….

Filed under:Biologics/DMARDsDrug Updates Tagged with:AmgenBiologicsBiosimilarsetanerceptetanercept-szzsLegalNovartis

kenary820 / shutterstock.com

Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis

Mary Choy, PharmD, BCGP, FASHP  |  April 15, 2019

Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:abataceptadalimumabapremilastbrodalumabCertolizumab PegoletanerceptGolimumabinfliximabixekizumabPsoriatic ArthritisRheumatic Drugs at a GlancesecukinumabTofacitinibtreatment guidelinesustekinumab

Biosimilars: How Do They Affect Patient Care & Safety?

Lara C. Pullen, PhD  |  March 19, 2019

CHICAGO—“We have got to get over this hump. We have got to try new stuff,” said Jacqueline M. Fritz, RN, MSN, CNS, to the audience gathered on the final day of the 2018 ACR/ARHP Annual Meeting, referring to the subject of biosimilars. Ms. Fritz, the owner and coordinator of education at the Medical Advancement Center…

Filed under:Biologics/DMARDsDrug UpdatesMeeting Reports Tagged with:2018 ACR/ARHP Annual Meetingadalimumab-attoetanercept-szzsfilgrastim-sndzinfliximab-abdainfliximab-dyyb

The Science Behind Biosimilars

Arthritis & Rheumatology  |  February 27, 2018

Although six biosimilar agents have now been approved by the U.S. Food & Drug Administration for use in rheumatology, scientific, clinical, economic and prescribing questions about the use of biosimilars abound. In fact, at the 2017 ACR/ARHP Annual Meeting in San Diego, Joseph Huffstutter, MD, a rheumatologist in private practice in Chattanooga, Tenn., said that…

Filed under:Biologics/DMARDsDrug UpdatesResearch Rheum Tagged with:Arthritis & RheumatologyBiologics & BiosimilarsBiosimilarsResearch

Should Patients with Rheumatic Disease Switch from Biologic to Biosimilar?

Susan Bernstein  |  January 19, 2018

SAN DIEGO—Should patients with rheumatic diseases switch from a biologic to its biosimilar? At the 2017 ACR/ARHP Annual Meeting’s Great Debate, held Nov. 5, two rheumatologists argued whether to switch or stay put based on safety, efficacy and potential cost savings. First to the podium to make the case for switching, Jonathan Kay, MD, tweaked…

Filed under:Biologics/DMARDsDrug UpdatesInsuranceMeeting Reports Tagged with:ACR/ARHP Annual MeetingBiologicsBiosimilarsdrug costinsurance

  • 1
  • 2
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences